Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK14 | O94921 | 14/20 | 0.47 |
| ▸ | CCNY | Q8ND76 | 14/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.46 |
| ▸ | CDK9 | P50750 | 2/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.46 |
| ▸ | CDK4 | P11802 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | CASK | O14936 | 1/20 | 0.46 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | MAK | P20794 | 1/20 | 0.46 |
| ▸ | CDK11B | P21127 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CCND3 | P30281 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22594205 | 0.99 | CDK14 (0.48) | CDK14CCNYCDK5CCNT1CDK9 | |
| SCHEMBL24757744 | 0.89 | CDK14 (0.49) | CDK14CCNYCDK5CCNT1CDK9 | |
| SCHEMBL24710272 | 0.87 | POLB (0.47) | CDK14CCNYCDK5CCNT1CDK9 | |
| SCHEMBL22582205 | 0.87 | CDK5 (0.46) | CDK14CCNYCDK5CCNT1CDK9 | |
| SCHEMBL8262979 | 0.87 | CDK5 (0.48) | CDK14CCNYCDK5CCNT1CDK9 | |
| SCHEMBL22582168 | 0.87 | CDK14 (0.43) | CDK14CCNYCDK5CCNT1CDK9 | |
| SCHEMBL3936062 | 0.86 | CDK14 (0.52) | CDK14CCNYCDK5CCNT1CDK9 | |
| SCHEMBL8262582 | 0.86 | CDK5 (0.46) | CDK14CCNYCDK5CCNT1CDK9 | |
| SCHEMBL22582208 | 0.86 | CDK5 (0.46) | CDK14CCNYCDK5CCNT1CDK9 | |
| SCHEMBL8212911 | 0.86 | CCNT1 (0.48) | CDK14CCNYCDK5CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114008058-B | Prodrugs of CDK inhibitors for the treatment of cancer | 润佳（苏州）医药科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-111848579-B | Prodrugs of 4- (2, 6-dichlorobenzoylamino) -N- (4-piperidinyl) -1H-pyrazole-3-carboxamide | 君实润佳(上海)医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11725020-B2 | Prodrugs of a CDK inhibitor for treating cancers | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-08-15 | — | — | US | disclosed |
| US-20220204541-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | SHANGHAI JUNSHI BIOSCIENCES CO., LTD. (CN) | 2022-06-30 | — | — | US | disclosed |
| CN-114008058-A | Prodrugs of CDK inhibitors for the treatment of cancer | 润佳（苏州）医药科技有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-11225497-B2 | Prodrugs of a CDK inhibitor for treating cancers | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-01-18 | — | — | US | disclosed |
| CN-111848579-A | Prodrugs of 4- (2, 6-dichlorobenzamido) -N- (4-piperidinyl) -1H-pyrazole-3-carboxamide | 润佳（苏州）医药科技有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200339615-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | SHANGHAI JUNSHI BIOSCIENCES CO., LTD. (CN) | 2020-10-29 | — | — | US | disclosed |
| WO-2020215156-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2020-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225497-B2 | Prodrugs of a CDK inhibitor for treating cancers | CDK3, CDK1, GSK3B | CDK14 25/4885CCNY 44/4885CDK5 26/4885 |
| US-20220204541-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | CDK3, CDK1, GSK3B | CDK14 25/4885CCNY 44/4885CDK5 26/4885 |
| US-11725020-B2 | Prodrugs of a CDK inhibitor for treating cancers | CDK3, CDK1, GSK3B | CDK14 25/4885CCNY 44/4885CDK5 26/4885 |
| US-20200339615-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | CDK3, CDK1, GSK3B | CDK14 25/4885CCNY 44/4885CDK5 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.